Nonmyeloablative Conditioning Combined with Anti-CD117 Antibody Briquilimab in Older Adults with High-Risk AML and MDS - PubMed
5 days ago
- #AML
- #MDS
- #Hematopoietic Cell Transplantation
- Briquilimab is a monoclonal antibody targeting CD117 (c-Kit) to inhibit stem cell factor (SCF) binding.
- Phase 1 trial combined briquilimab with non-myeloablative fludarabine and TBI for older adults with high-risk AML/MDS undergoing allogeneic HCT.
- 32 patients enrolled (13 AML in CR, 3 AML in relapse, 16 MDS) with a median age of 70.
- No briquilimab infusion reactions, dose-limiting toxicities, or primary graft failures observed.
- 1-year EFS was 69.2% for AML in CR and 53.8% for MDS; 1-year OS was 75% and 76.4%, respectively.
- Briquilimab depleted AML/MDS HSPCs by 62.4±22.7% and increased serum SCF threefold.
- Study confirms feasibility, safety, and proof of concept for CD117-targeted conditioning in AML/MDS HCT.